Infant leukemia is leukemia diagnosed before a child’s first birthday. It is rare, but it behaves differently from leukemia in older children: it is often driven by a change in the KMT2A gene (formerly called MLL) that begins before birth, it tends to present with very high white cell counts, and it needs treatment designed around a baby’s still-developing body. Below I cover what causes it, how it is diagnosed, and how modern treatment works.
What Is Infant Leukemia?
Leukemia is a cancer of blood-forming cells in the bone marrow. Immature cells called blasts multiply uncontrollably and crowd out the normal production of red cells, white cells, and platelets. To understand why this causes so many symptoms, it helps to know the composition and function of bone marrow.
In infants, two main types occur:
- Acute lymphoblastic leukemia (ALL): the more common type in infants, arising from early lymphoid cells.
- Acute myeloid leukemia (AML): arising from early myeloid cells; it makes up a larger share of cases in infants than in older children.
Leukemia present at birth or within the first four weeks is called congenital leukemia. For a symptom-focused companion piece, see this overview of infant leukemia symptoms and treatment.
Causes and Risk Factors
Most parents’ first question is “Did we do something to cause this?” The answer is almost always no. No lifestyle choice by the parents has been shown to cause infant leukemia.
The KMT2A gene rearrangement
The central event in most infant ALL, and in a substantial share of infant AML, is a KMT2A rearrangement. Part of the KMT2A gene breaks and fuses with a partner gene on another chromosome. The resulting fusion protein switches on genes that keep cells immature and dividing.
Evidence from studies of identical twins and newborn blood samples shows that this change starts in the womb. Unlike most childhood leukemias, which appear to need several genetic “hits,” KMT2A-rearranged leukemia seems to need very few additional changes, which may explain how quickly it develops.
Other risk factors
- Down syndrome: newborns can develop a temporary blood disorder called transient abnormal myelopoiesis, and a minority later develop a form of AML.
- Inherited predisposition syndromes: rare conditions that affect DNA repair or blood development.
- Prenatal exposures: exposure to certain chemicals or medications during pregnancy has been studied as a possible trigger, but no exposure has been proven to cause it.
Signs and Symptoms
Babies cannot describe how they feel, so the signs are often picked up by parents or at routine checks. Many reflect bone marrow failure, where normal blood production is squeezed out.
- Pallor, poor feeding, and irritability from anemia.
- Bruising, tiny red skin spots (petechiae), or bleeding from low platelet counts.
- Fevers and frequent infections from a lack of normal white cells.
- A swollen abdomen from an enlarged liver and spleen.
- Firm bluish or purple skin bumps (leukemia cutis), more typical of infant AML.
- Bulging fontanelle, vomiting, or unusual drowsiness if leukemia involves the brain and spinal fluid.
How Infant Leukemia Is Diagnosed
Diagnosis moves quickly once leukemia is suspected. The main steps are:
| Test | What it shows |
|---|---|
| Complete blood count and blood film | High or low white count, anemia, low platelets, and circulating blasts |
| Bone marrow aspirate and biopsy | Confirms leukemia and provides cells for further tests |
| Flow cytometry (immunophenotyping) | Identifies ALL versus AML and the exact cell lineage |
| Cytogenetics and molecular testing | Detects KMT2A rearrangements and other genetic changes |
| Lumbar puncture | Checks the spinal fluid for leukemia cells |
| Heart ultrasound and baseline organ tests | Checks fitness for chemotherapy, especially anthracyclines |
Genetic results matter a great deal. Whether a KMT2A rearrangement is present, and the baby’s age at diagnosis, are among the strongest factors used to assign risk and choose therapy. Infants under about six months with KMT2A-rearranged ALL are generally treated as higher risk.
Modern Treatment of Infant Leukemia
Infant leukemia is treated in specialist pediatric oncology centers, usually on infant-specific protocols developed through international collaboration. Doses are carefully adjusted, because a baby’s liver, kidneys, and brain handle drugs differently from an older child’s.
Chemotherapy
For ALL, treatment combines drugs such as corticosteroids, vincristine, asparaginase, and antimetabolites, with elements borrowed from AML regimens such as cytarabine because infant ALL cells often share myeloid features. For AML, the backbone is cytarabine combined with an anthracycline. Treatment is also delivered into the spinal fluid to prevent or treat brain involvement.
Immunotherapy and targeted therapy
Newer approaches have been added to infant ALL protocols, including bispecific antibody therapy that directs the child’s T cells against leukemia cells carrying the CD19 marker. Menin inhibitors, drugs that block a protein KMT2A-rearranged leukemia depends on, are an active area of study. CAR T-cell therapy is used in some relapsed cases, although experience in very young infants is limited.
Stem cell transplantation
Allogeneic stem cell transplant is considered for the highest-risk infants or those who respond poorly to initial therapy. Its role is weighed carefully against the long-term effects of transplant at such a young age.
Supportive care
Transfusions, infection prevention, nutrition support, and close growth and development monitoring are as important as the chemotherapy itself. Families also need practical and emotional support through a long treatment course.
When to See a Doctor
Most pale, fussy, or bruised babies do not have leukemia. Still, see a doctor promptly if your baby has unexplained bruises or pinpoint spots, persistent pallor, a swollen belly, repeated fevers, unusual skin lumps, or is feeding poorly and unusually sleepy. A simple blood count is the first step and can be done quickly.
For more on leukemia types across all ages, visit the leukemia guide.
Frequently Asked Questions
What causes leukemia in babies?
Most cases arise from a genetic change, usually a KMT2A rearrangement, that begins before birth. It is not inherited in the usual sense and is not caused by anything the parents did. Down syndrome and some rare predisposition syndromes raise the risk.
Is infant leukemia harder to treat than leukemia in older children?
Generally yes, especially KMT2A-rearranged ALL in the youngest babies. Outcomes are better for infants without this rearrangement. Newer immunotherapy and targeted approaches are being added specifically to improve results in the high-risk group.
How is infant leukemia confirmed?
A blood count raises the suspicion, and a bone marrow test confirms it. Flow cytometry identifies the type, and genetic testing looks for KMT2A and other changes that guide treatment.
Will my baby have long-term effects from treatment?
Some children do, including effects on growth, heart function, hearing, or learning, depending on the treatment received. That is why survivors are followed in long-term clinics that check for these effects and act early.
